Rezolute Inc. Common Stock (NV) (RZLT)
RZLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | RZLT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001509261 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NV |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $8.2M cash; operating cash flow -$16.5M a quarter. | Report 2026-09-30 |
| Shares outstanding | 96,728,913 (2026-11-02); 92,727,532 a year earlier; 39,625,271 three years earlier. | Cover page 2026-11-02 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-11-13 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton LLP, Newport Beach, California, United States | PCAOB Form AP 2026-10-07 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $231K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | -$18.5M | -$18.8M | $8.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2026 2026-06-30 | Not filed | -$20.5M | -$13.1M | $10.6M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q3 2026 2026-03-31 | Not filed | -$16.2M | -$13.7M | $11.2M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q2 2026 2025-12-31 | Not filed | -$22.8M | -$20.3M | $11.9M | No debt tags | Needs four quarters | 10-Q 2026-02-12 |
| Q1 2026 2025-09-30 | Not filed | -$18.1M | -$17.4M | $9.1M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q4 2025 2025-06-30 | Not filed | -$24.4M | -$22.0M | $94.1M | No debt tags | Needs four quarters | 10-K 2026-09-24 |
| Q3 2025 2025-03-31 | Not filed | -$18.9M | -$17.4M | $14.6M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q2 2025 2024-12-31 | Not filed | -$15.7M | -$13.7M | $8.9M | No debt tags | Needs four quarters | 10-Q 2026-02-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-11-16 |
| Latest annual report | 10-K | 2026-09-24 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report FORM 8-K | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-10-21 |
Source: SEC EDGAR submissions feed, 767 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -5.8% |
| 1 month | -20.7% |
| 3 months | -20.5% |
| Year to date | +54.9% |
| 1 year | -63.2% |
| From 52-week high | -66.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ASPE | Aspen Neuroscience Inc. | $12.23 | -2.86% | $355.6M |
| SPRY | ARS Pharmaceuticals Inc. | $3.59 | -7.71% | $360.9M |
| AVIR | Atea Pharmaceuticals Inc. | $4.12 | -4.19% | $330.9M |
| PBYI | Puma Biotechnology Inc | $7.34 | -5.53% | $379.5M |
| CTNM | Contineum Therapeutics Inc. | $9.67 | -1.93% | $379.7M |
| CRMD | CorMedix Inc. | $4.82 | +3.43% | $383.4M |
| LRMR | Larimar Therapeutics Inc. | $3.00 | -0.66% | $311.6M |
| RLMD | Relmada Therapeutics Inc. | $3.61 | -14.25% | $385.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier